New FDA policy on compounding GLP-1 drugs New FDA policy on compounding GLP-1 drugs On April 24, 2025, FDA announced that licensed pharmacies and physicians can no longer compound semaglutide (a GLP-1 drug used in Ozempic & Wegovy) and outsourcing facilities must stop production by May 22, 2025
For people over 60, the need for glutathione increases significantly and we recommend daily maintenance doses of both Trizomal Glutathione and Glutathione Recycler
Wu F, Smith MR, Mueller AL, Klapman SA, Everett LL, Houle T, et al
ASDA Online Doctor doesn't recommend getting a type 2 diabetes medication prescribed off-label
The Dermaroller Comparison Study One of the most significant studies directly examined copper peptides for acne scars